Insight Advisors’s Exact Sciences EXAS Stock Holding History

Insight Advisors’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,625	Closed	-$341K	–	318
2021 Q1	$341K	Buy	+2,625	New	+$359K	0.11%	237

Other funds holding EXAS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Insight Advisors's EXAS Position: Q2 2021 in Review

Insight Advisors sold out of Exact Sciences (EXAS) in Q2 2021, closing a stake of 2,625 shares — an estimated $341K sold.

Insight Advisors first reported a position in EXAS in Q1 2021 and held it in 1 quarter. The position peaked at $341K in Q1 2021. 622 funds tracked by Wall St. Rank hold EXAS as of Q2 2021.

Insight Advisors reported no remaining Exact Sciences position as of Q2 2021 after selling out during the quarter.
Insight Advisors sold 2,625 Exact Sciences shares in Q2 2021, an estimated $341K.
Insight Advisors first reported a position in Exact Sciences in Q1 2021 and held it in 1 quarter.
Insight Advisors's Exact Sciences position peaked at $341K in Q1 2021.
622 funds tracked by Wall St. Rank held Exact Sciences as of Q2 2021.

Based on Insight Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.